Clinical Trial

A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera

Study acronym: VERIFY
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The study is designed to evaluate the safety and efficacy of rusfertide in subjects with polycythemia vera (PV) in maintaining hematocrit control and in improving symptoms of PV.
Protocol Amendment History 27 amendments
This ClinicalTrials.gov record has been amended 27 times since 2022-01-14; most recent amendment 2025-08-04.
Status change: Recruiting → Active, Not Recruiting 2024-07-15
Status change: Not Yet Recruiting → Recruiting 2022-03-15
Trial Details
NCT Number NCT05210790
Lead Sponsor Protagonist Therapeutics, Inc.
Conditions Polycythemia Vera
Enrollment 293 participants
Start Date 2022-04-01
Primary Completion 2025-02-21 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2025-08-07